Skip to main content

Relias Media has upgraded our site!

Please bear with us as we work through some issues in order to provide you with a better experience.

Thank you for your patience.

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Relying on careful monitoring to reduce the risk of toxicity, Ritchie and colleagues carried out a 36-week phase II test of the efficacy of clioquinol in reducing plasma beta-amyloid levels and slowing cognitive decline in patients with moderately severe Alzheimer's disease.

Alzheimer Metal Chelator Shows Some Promise in Phase II